Allena Pharmaceuticals, Inc. Change in payables and accrued liability

Change in payables and accrued liability of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Change in payables and accrued liability growth rates and interactive chart.


Highlights and Quick Summary

  • Change in payables and accrued liability for the quarter ending March 31, 2022 was $-2.79 Million (a 39.65% increase compared to previous quarter)
  • Year-over-year quarterly Change in payables and accrued liability increased by 711.92%
  • Annual Change in payables and accrued liability for 2021 was $-1.38 Million (a 153.13% increase from previous year)
  • Annual Change in payables and accrued liability for 2020 was $-544 Thousand (a -155.97% decrease from previous year)
  • Annual Change in payables and accrued liability for 2019 was $972 Thousand (a 120.41% increase from previous year)
  • Twelve month Change in payables and accrued liability ending March 31, 2022 was $-4.64 Million (a 236.82% increase compared to previous quarter)
  • Twelve month trailing Change in payables and accrued liability decreased by -324.17% year-over-year
Trailing Change in payables and accrued liability for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-4.64 Million $-1.38 Million $2 Million $2.07 Million
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Change in payables and accrued liability of Allena Pharmaceuticals, Inc.

Most recent Change in payables and accrued liabilityof ALNA including historical data for past 10 years.

Interactive Chart of Change in payables and accrued liability of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Change in payables and accrued liability for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-2.79
2021 $-2.0 $0.5 $-0.34 $0.47 $-1.38
2020 $1.38 $0.57 $-0.01 $-1.5 $-0.54
2019 $0.09 $0.48 $0.09 $-0.96 $0.97
2018 $0.46 $1.31 $0.6 $-0.62 $0.44
2017 $0.36 $0.63 $0.06 $-0.82 $0.2
2016 $0.23 $0.69
2015 $0.22

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.